Understanding a company’s financial performance is one of the most important steps before applying for an IPO. In this article, we break down the key financial numbers of Sudeep Pharma Ltd for FY23, FY24 and FY25, including its revenue, profit, borrowings, net worth and total assets. This will help investors judge the company’s growth, stability and overall financial health.
Revenue From Operations (Growth Trend)
Sudeep Pharma has shown steady growth in revenue over the last three financial years.
| Financial Year | Revenue (₹ crore) |
|---|---|
| FY23 | 428 |
| FY24 | 459 |
| FY25 | 502 |
Analysis:
- Revenue grew consistently each year.
- FY23 → FY25 total revenue growth = ~17% in two years.
- This signals healthy demand for the company’s products and stable business operations.
Net Profit (After Tax)
The company’s net profit has increased sharply, showing strong profitability.
| Year | Net Profit (₹ crore) |
|---|---|
| FY23 | 226 |
| FY24 | 359 |
| FY25 | 497 |
Analysis:
- Profit nearly doubled from FY23 to FY25.
- Strong profit growth indicates better margins, cost control, and improving business scale.
- Higher profits strengthen the company’s valuation for IPO investors.
PAT (Profit After Tax)
PAT also reflects the company’s final bottom-line performance.
| Year | PAT (₹ crore) |
|---|---|
| FY23 | 62 |
| FY24 | 133 |
| FY25 | 138 |
Analysis:
- PAT more than doubled from FY23 to FY24.
- FY25 PAT is slightly higher than FY24, indicating stable profitability.
- The business has maintained consistent earnings even after taxes.
Borrowings (Debt Position)
Borrowings show how much debt the company is carrying.
| Year | Borrowings (₹ crore) |
|---|---|
| FY23 | 82 |
| FY24 | 75 |
| FY25 | 135 |
Analysis:
- Debt decreased from FY23 to FY24.
- But FY25 borrowings increased to 135 crore.
- This could mean expansion, new capacity creation, or working capital needs.
- Investors must check IPO prospectus to see why debt increased.
Total Assets (Balance Sheet Strength)
Total assets show how much the company owns — including plants, equipment, property, cash and investments.
| Year | Total Assets (₹ crore) |
|---|---|
| FY23 | 420 |
| FY24 | 513 |
| FY25 | 717 |
Analysis:
- Assets have grown significantly — an increase of ~71% in two years.
- Indicates expansion, investments into production capacity, and business scaling.
- Higher assets usually mean stronger long-term stability.
Overall Financial Health Summary
Revenue is steadily increasing
This shows strong market demand and consistent performance.
Net profit is rising sharply
The company is improving its profitability year after year.
PAT is stable and healthy
Indicates long-term earnings visibility.
Assets growing faster than debt
Suggests business expansion and solid financial backing.
⚠️ Borrowings increased in FY25
Investors should check the RHP for the reason behind this rise.
Conclusion: Is Sudeep Pharma Financially Strong?
Based on FY23–FY25 numbers, Sudeep Pharma Ltd shows strong financial growth, profitability and expanding asset base.
Rising revenue and profits make the company look fundamentally strong, though the spike in FY25 borrowings should be reviewed before investing.
This financial trend positions Sudeep Pharma as a potentially attractive IPO candidate for both listing gains and long-term investors.
source- NSE
I am a finance writer focused on IPO updates, market trends and equity research. I simplify complex IPO data into clear, accurate and reliable insights to help readers stay informed.